Carfilzomib For Injection

Product Description

Carfilnat Injection is an anti-cancer medication. It works by blocking or slowing the breakdown of proteins in cells. As a result, there is an increase in a number of proteins in the cancer cells leading to their death.

1. What is Carfilzomib for Injection?

   • Carfilzomib is a medication used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow.

2. How does Carfilzomib work?

   • Carfilzomib is a proteasome inhibitor, which means it interferes with the activity of proteasomes, structures within cells that break down proteins. By inhibiting proteasomes, carfilzomib helps to kill cancer cells and slow the progression of multiple myeloma.

3. What are the common side effects of Carfilzomib?

   • Common side effects of carfilzomib may include fatigue, nausea, diarrhea, fever, shortness of breath, low blood cell counts, and peripheral neuropathy (nerve damage).

4. How is Carfilzomib administered?

   • Carfilzomib is typically given as an intravenous (IV) infusion by a healthcare professional in a clinic or hospital setting. The dosing schedule and frequency may vary depending on the individual's condition and response to treatment.

5. Who can take Carfilzomib?

   • Carfilzomib is generally prescribed for adults with relapsed or refractory multiple myeloma who have received one or more prior lines of therapy.

6. Are there any precautions or contraindications for using Carfilzomib?

   • Carfilzomib may not be suitable for individuals with certain pre-existing medical conditions, such as heart disease or liver problems. It may also interact with other medications, so it's important to inform your healthcare provider about all medications you are taking. Additionally, pregnant or breastfeeding women should discuss the risks and benefits of carfilzomib with their healthcare provider.

7. How effective is Carfilzomib in treating multiple myeloma?

   • Carfilzomib has been shown to be effective in the treatment of relapsed or refractory multiple myeloma, both as a single agent and in combination with other medications. Clinical trials have demonstrated its ability to improve response rates, progression-free survival, and overall survival in patients with multiple myeloma.

8. What should I do if I miss a dose of Carfilzomib?

   • If you miss a dose of carfilzomib, contact your healthcare provider as soon as possible to reschedule your appointment and discuss any necessary adjustments to your treatment plan.

9. Are there any long-term effects or risks associated with Carfilzomib treatment?

   • Long-term effects of carfilzomib treatment may include cumulative toxicity, such as cardiac or renal toxicity, which may require monitoring and management by healthcare professionals. Your healthcare provider can provide guidance on managing potential long-term effects and risks associated with carfilzomib therapy.

10. Where can I find more information about Carfilzomib for Injection?

    • Additional information about carfilzomib, including its mechanism of action, clinical trials, and prescribing information, can be obtained from your healthcare provider or the manufacturer's website. Additionally, patient advocacy organizations and support groups may offer resources and support for individuals undergoing treatment for multiple myeloma.

Proteasome Inhibitor Therapy for Multiple Myeloma

Carfilzomib offers advanced treatment by targeting proteasome activity, instrumental in managing relapsed or refractory multiple myeloma. Its mechanism improves therapeutic outcomes for patients who have previously received other treatments. Administered intravenously, this drug requires prescription oversight, ensuring safe and effective cancer care. Healthcare professionals closely monitor individuals taking Carfilzomib, particularly considering its impact on kidney and heart functions during therapy.


Sterile Lyophilized Powder

Packaged as a sterile lyophilized powder, Carfilzomib is supplied in a single-use vial for intravenous administration. The powder presents as white to off-white and is completely odorless, providing clarity about its purity and stability. Prior to injection, the powder must be accurately reconstituted with sterile water, maintaining its neutral pH and ensuring patient safety throughout the preparation process.


Safe Storage and Handling

Maintaining Carfilzomib's efficacy requires diligent storage conditions between 2C and 8C. The product offers a two-year shelf life when stored correctly, upholding its pharmaceutical integrity. Strict preservation enhances both safety and effectiveness of each dose. Healthcare facilities, retailers, and wholesalers in India follow regulated protocols for product handling, storage, and distribution, supporting optimal patient care.